Loading...
Market
What will be the status of BridgeBio by September 30, 2025?
2
Resolution / Starting Odds
Acquired by another company • 25%
Forms a major collaboration • 25%
Remains independent • 25%
Other • 25%
Company press releases and financial news sources
Story
BridgeBio's Infigratinib Receives FDA Breakthrough Therapy Designation, Stock Surges 64.2%
Sep 17, 2024, 11:32 AM
BridgeBio Pharma announced that its investigational therapeutic, infigratinib, has been awarded Breakthrough Therapy Designation by the FDA. This marks the first time such a designation has been given to a treatment for achondroplasia. The designation is expected to expedite the development and review of infigratinib, which is being developed as an oral treatment for children with achondroplasia. Following this announcement, BridgeBio's stock ($BBIO) surged by 64.2%.
View original story
Similar markets
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Above $1 billion • 25%
Between $750 million and $1 billion • 25%
Between $500 million and $750 million • 25%
Below $500 million • 25%
Yes • 50%
No • 50%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Significant growth • 25%
Moderate growth • 25%
No change • 25%
Decline • 25%
Yes • 50%
No • 50%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Remain within 10% of current price • 25%
Decrease by more than 10% • 25%